Oral LD50 in rat is 183 mg/kg.
Dipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Mianserin | The therapeutic efficacy of Dipivefrin can be decreased when used in combination with Mianserin. |
| Formoterol | Dipivefrin may increase the sympathomimetic activities of Formoterol. |
| Oxymetazoline | Dipivefrin may increase the hypertensive and vasoconstricting activities of Oxymetazoline. |
| Vasopressin | Vasopressin may increase the hypertensive activities of Dipivefrin. |
| Methacholine | Dipivefrin may decrease effectiveness of Methacholine as a diagnostic agent. |
| Methyclothiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Methyclothiazide. |
| Bendroflumethiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Bendroflumethiazide. |
| Benzthiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Benzthiazide. |
| Cyclothiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Cyclothiazide. |
| Hydroflumethiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Hydroflumethiazide. |
| Chlorothiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Chlorothiazide. |
| Hydrochlorothiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Hydrochlorothiazide. |
| Trichlormethiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Trichlormethiazide. |
| Polythiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Polythiazide. |
| Mebutizide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Mebutizide. |
| Cyclopenthiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Cyclopenthiazide. |
| Buthiazide | The risk or severity of hypokalemia can be increased when Dipivefrin is combined with Buthiazide. |
| Caffeine | The risk or severity of hypokalemia can be increased when Caffeine is combined with Dipivefrin. |
| Theophylline | The risk or severity of hypokalemia can be increased when Theophylline is combined with Dipivefrin. |
| Dyphylline | The risk or severity of hypokalemia can be increased when Dyphylline is combined with Dipivefrin. |
| Pentoxifylline | The risk or severity of hypokalemia can be increased when Pentoxifylline is combined with Dipivefrin. |
| Mercaptopurine | The risk or severity of hypokalemia can be increased when Mercaptopurine is combined with Dipivefrin. |
| Aminophylline | The risk or severity of hypokalemia can be increased when Aminophylline is combined with Dipivefrin. |
| Oxtriphylline | The risk or severity of hypokalemia can be increased when Oxtriphylline is combined with Dipivefrin. |
| Theobromine | The risk or severity of hypokalemia can be increased when Theobromine is combined with Dipivefrin. |
| Fenethylline | The risk or severity of hypokalemia can be increased when Fenethylline is combined with Dipivefrin. |
| 8-azaguanine | The risk or severity of hypokalemia can be increased when 8-azaguanine is combined with Dipivefrin. |
| 7,9-Dimethylguanine | The risk or severity of hypokalemia can be increased when 7,9-Dimethylguanine is combined with Dipivefrin. |
| Xanthine | The risk or severity of hypokalemia can be increased when Xanthine is combined with Dipivefrin. |
| 7-Deazaguanine | The risk or severity of hypokalemia can be increased when 7-Deazaguanine is combined with Dipivefrin. |
| Guanine | The risk or severity of hypokalemia can be increased when Guanine is combined with Dipivefrin. |
| 9-Methylguanine | The risk or severity of hypokalemia can be increased when 9-Methylguanine is combined with Dipivefrin. |
| Peldesine | The risk or severity of hypokalemia can be increased when Peldesine is combined with Dipivefrin. |
| Hypoxanthine | The risk or severity of hypokalemia can be increased when Hypoxanthine is combined with Dipivefrin. |
| 9-Deazaguanine | The risk or severity of hypokalemia can be increased when 9-Deazaguanine is combined with Dipivefrin. |
| Propentofylline | The risk or severity of hypokalemia can be increased when Propentofylline is combined with Dipivefrin. |
| Valomaciclovir | The risk or severity of hypokalemia can be increased when Valomaciclovir is combined with Dipivefrin. |
| 3-isobutyl-1-methyl-7H-xanthine | The risk or severity of hypokalemia can be increased when 3-isobutyl-1-methyl-7H-xanthine is combined with Dipivefrin. |
| Uric acid | The risk or severity of hypokalemia can be increased when Uric acid is combined with Dipivefrin. |
| Doxofylline | The risk or severity of hypokalemia can be increased when Doxofylline is combined with Dipivefrin. |
| 6-O-benzylguanine | The risk or severity of hypokalemia can be increased when 6-O-benzylguanine is combined with Dipivefrin. |
| Lisofylline | The risk or severity of hypokalemia can be increased when Lisofylline is combined with Dipivefrin. |
| Lobucavir | The risk or severity of hypokalemia can be increased when Lobucavir is combined with Dipivefrin. |
| Cafedrine | The risk or severity of hypokalemia can be increased when Cafedrine is combined with Dipivefrin. |
| Theodrenaline | The risk or severity of hypokalemia can be increased when Theodrenaline is combined with Dipivefrin. |
| Bamifylline | The risk or severity of hypokalemia can be increased when Bamifylline is combined with Dipivefrin. |
| Proxyphylline | The risk or severity of hypokalemia can be increased when Proxyphylline is combined with Dipivefrin. |
| Acefylline | The risk or severity of hypokalemia can be increased when Acefylline is combined with Dipivefrin. |
| Etamiphylline | The risk or severity of hypokalemia can be increased when Etamiphylline is combined with Dipivefrin. |
| Pentifylline | The risk or severity of hypokalemia can be increased when Pentifylline is combined with Dipivefrin. |
| Bufylline | The risk or severity of hypokalemia can be increased when Bufylline is combined with Dipivefrin. |
| Bromotheophylline | The risk or severity of hypokalemia can be increased when Bromotheophylline is combined with Dipivefrin. |
| Furafylline | The risk or severity of hypokalemia can be increased when Furafylline is combined with Dipivefrin. |
| 8-chlorotheophylline | The risk or severity of hypokalemia can be increased when 8-chlorotheophylline is combined with Dipivefrin. |
| PCS-499 | The risk or severity of hypokalemia can be increased when PCS-499 is combined with Dipivefrin. |
| Lomifylline | The risk or severity of hypokalemia can be increased when Lomifylline is combined with Dipivefrin. |